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Patients with mild hypomegakaryocytic thrombocytopenia (HMT) that does 
not meet the diagnostic criteria for a definite disease entity may potentially 
progress to aplastic anaemia (AA) refractory to therapy. To clarify the clinical 
pictures of HMT, we prospectively followed 25 HMT patients that fulfilled 
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the following criteria: a WBC count of >3.0x109/l, an Hb level of >10g/dl, and 
a platelet count of <100.0x109/l in the absence of morphological and 
karyotypic abnormalities in the bone marrow. 
Glycosylphosphatidylinositol-anchored protein-deficient blood cells 
(PNH-type cells) were detected in 7 of the 25 (28%) patients and elevated 
plasma thrombopoietin (TPO) levels (>320 pg/ml) were observed in 11 (44%) 
patients. Five (four PNH+ and one PNH-) of six TPOhigh patients who were 
treated with cyclosoporine (CsA) showed improvement. Among the 21 
patients who were followed without treatment, thrombocytopenia progressed 
in four of ten TPOlow patients and four of 11 TPOhigh patients. The three-year 
failure-free survival rate of the TPOhigh patients who were treated with CsA 
(100%) was significantly higher than that of the untreated TPOhigh patients 
(20%). These results suggest that a significant population of HMT patients 
has an immune pathophysiology that is similar to AA and may be improved 
by early therapeutic intervention with CsA. 
 






Mild thrombocytopenia without anaemia and leukopenia is associated with 
various haematologic diseases, including immune thrombocytopenic purpura 
(ITP) (Provan, et al 2010) and myelodysplastic syndromes (MDS) (Cheson, et 
al 2006, Valent, et al 2007). There is, however, a considerable number of 
cases that do not meet the diagnostic criteria for such established diseases, 
due to megakaryocytic hypoplasia in patients with ITP and the absence of 
dysplastic signs in the bone marrow (BM) cells. When their 
thrombocytopenia is mild (≥50 x 109/L)(Provan, et al 2010), these patients 
are usually followed without therapy. However, some patients with 
hypomegakaryocytic thrombocytopenia (HMT) may progress to aplastic 
anaemia (AA), which is refractory to immunosuppressive therapy (IST), after 
long-term observation, just like the patients with moderate AA who were 
followed without IST(Nishio, et al 2009). It is therefore important to 
elucidate the pathophysiology of HMT at the time of diagnosis, even in 
patients without severe thrombocytopenia.  
We previously conducted a retrospective analysis of 29 HMT patients that 
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fulfilled the following criteria: a WBC count of >3.0x109/l, an Hb level of 
>10g/dl, and a platelet count of <100.0x109/l in the absence of morphological 
and karyotypic abnormalities in BM with megakaryocytic hypoplasia, and 
found that 55% of the patients possessed an increased number of 
glycosylphosphatidylinositol (GPI)-anchored protein (GPI-AP)-deficient 
blood cells (PNH-type cells). PNH-type cells, which are often detected in 
patients with AA, are associated with a better response to IST than that 
which is observed in patients without PNH-type cells (Kulagin, et al 2014, 
Sugimori, et al 2006, Wang, et al 2001, Wang, et al 2002). In this 
retrospective analysis, 10 of the 16 patients with PNH-type cells (PNH[+] 
patients) received cyclosporine (CsA) monotherapy;  60% of them responded 
to the therapy (unpublished observation). On the other hand, 
thrombocytopenia patients with megakaryocyte deficiency have high plasma 
thrombopoietin (TPO) levels (Emmons, et al 1996) and our previous study 
demonstrated that low-risk MDS patients with high (>320 pg/ml) TPO levels 
are more likely to respond to IST and that they show a better prognosis than 
patients with low (<320 pg/ml) TPO levels (Seiki, et al 2013). All of these 
findings suggest the presence of immune mechanisms in a subset of patients 
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with HMT. To further characterize the clinical pictures and the prognosis of 
HMT, we conducted a multicenter prospective observational study 
(UMIN-CTR 000002729). We herein report the results of an interim analysis 
of this study.  
 
Patients and Methods 
Patients 
A nationwide observational study of patients with HMT was started in 
January 2010. The inclusion criteria were as follows: a white blood cell 
(WBC) count of > 3x109/L, a haemoglobin (Hb) level of >10 g/dL and a 
platelet (Plt) count of <100×109/L with a decreased number of 
megakaryocytes in the BM. The megakaryocyte cellularity was determined 
by a pathologist on trephine biopsy sections, and only those patients who 
showed a decrease in the number of megakaryocytes were enrolled in this 
study. The decrease in the number of megakaryocytes was defined as 1 
megakaryocyte per 5 to 10 low-power fields or <10/mm2. The patients who 
met the diagnostic criteria for well-established hematological diseases, 
including ITP (Provan, et al 2010), AA (Marsh, et al 2009), MDS (Cheson, et 
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al 2006, Valent, et al 2007) and PNH (Parker, et al 2005) were excluded from 
the present study. The therapeutic strategies were left to each physician’s 
discretion. This study was approved by the institutional review boards of all 
of the institutions that participated this study (no. 796), and all patients 
provided written informed consent prior to sampling. 
 
Detection of PNH-type cells  
PNH-type cells were detected by a high-sensitivity flow cytometry (FCM) 
assay, which was performed at the time of diagnosis and annually thereafter. 
The analysis was performed according to a previously described method 
(Araten, et al 1999, Sugimori, et al 2006) . The cutoff values of the assay 
were >0.003% for granulocytes and >0.005% for erythrocytes (Kulagin, et al 
2014, Parker, et al 2005, Sugimori, et al 2009).  
 
Measurement of plasma TPO  
TPO levels were determined at the time of enrollment. All peripheral blood 
samples were sent to SRL Inc. (Tokyo, Japan) to measure the plasma TPO 
levels using a Chemiluminescent Enzyme Immunoassay (CLEIA). Briefly, 
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standard rhTPO (FUJIREBIO, Tokyo, Japan) and plasma samples were 
incubated in plate wells that were coated with mouse anti-human 
anti-rhTPO antibody (FUJIREBIO, Tokyo, Japan). Biotinylated rabbit 
anti-human rhTPO antibodies (FUJIREBIO, Tokyo, Japan) were added as 
the primary antibody. After incubation with streptavidin-alkaline 
phosphatase-labeled secondary antibodies (DAKO, Glostrup, Denmark), 
Substrate/Enhancer solution (Life Technologies, Carlsbad, CA, USA) was 
added, and the relative chemiluminescence intensity was measured using a 
luminometer (Molecular Device, Sunnyvale, CA, USA). 
 
Statistical methods 
The laboratory parameters were compared between subgroups with different 
TPO levels. Fisher’s exact test was used to analyze the prevalence of 
increased PNH-type cells and the Mann-Whitney U test was used for the 
analyses of the other clinical parameters.  P values of <0.05 were considered 
to indicate statistical significance. All of the P -values were two-sided. The 
overall and failure-free survival rates were calculated according to the 
Kaplan-Meier method and the findings were compared using the log-rank 
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test. Treatment failure was defined as death or the progression of 
thrombocytopenia. We defined the progression of thrombocytopenia as a 
decrease in the platelet count by 10×109/L from the count at the time of 
enrollment. All of the statistical analyses were performed using the EZR 
software package (Saitama Medical Center, Jichi Medical University, 
Saitama, Japan), a graphical user interface for the R software program (The 




Twenty-five HMT cases (male/female, 14/11) were enrolled in this study from 
August 2010 to March 2014, and the data for this interim analysis were 
collected in July 2015. The median follow-up period was 41 months (range, 
19-59 months). The patient characteristics are shown in Table I. The median 
age was 65 years (range, 25-79 years). The mean values of the complete blood 
cell counts were as follows: WBC count, 4.1 x109/L (range, 2.77-8.50 x109/L); 
Hb level, 11.9 g/dl (range, 10.0-14.8 g/dl), and platelet count, 40.0 x109/L 
(range, 1.0-95.0 x109/L). PNH-type cells were detected in 7 of the 25 cases 
9 
 
(28%); the median clone sizes of the PNH-type cells were 0.073% (range, 
0.015% - 20.5%) in granulocytes and 0.069% (range, 0% - 3.8%) in 
erythrocytes. Figure 1 shows representative scattergrams of PNH-type cells 
in three PNH(+) patients. 
 
The plasma TPO levels and their correlation with other laboratory 
parameters 
The median TPO level was 290 pg/ml (range, 14-1510 fmol/ml). Eleven (44%) 
patients had TPO levels of >320 pg/ml (TPOhigh patients), which was the 
lowest TPO level of patients with low-risk MDS whose pathophysiology was 
similar to that of AA (Seiki, et al 2013). Table II shows the relationships 
between the TPO levels and the clinical characteristics. When the clinical 
data in the TPOhigh patients and the patients with TPO levels of <320 pg/ml 
(TPOlow patients) were compared, the TPOhigh patients showed significantly 
lower Hb levels (11.0 vs 12.4, P<0.01) and a higher prevalence of increased 
PNH-type cells (64% vs 0%, P<0.001) in comparison to the TPOlow patients.  
 
Clinical course  
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The clinical courses could be followed in 11 TPOhigh and 10 TPOlow patients 
for a median of 27 months (range, 12 to 48 months) after their enrollment. 
Six of the 11 TPOhigh patients were treated with CsA while all of the TPOlow 
patients were left untreated. Five of the six (PNH[+], n=4; PNH[-], n=1; 83%) 
TPOhigh patients responded well to CsA. The remaining patient who did not 
respond to CsA therapy was negative for PNH-type cells. The changes in the 
blood cell counts of the five patients are shown in Table III. 
Thrombocytopenia recurred in one TPOhigh with PNH(+) patient in 
association with a dose-reduction of CsA. No toxicities greater than grade 2 
developed in any of the patients who were treated with CsA in this study. 
Thrombocytopenia progressed in 4 of the 5 (80%) TPOhigh (three PNH+ 
and two PNH-) patients who were followed without IST. Notably, two of the 
four progressive patients developed moderate AA at 12 and 15 months after 
the diagnosis of HMT (Figs 2 and S1A) and one died of sepsis at 24 months.   
Among the 10 TPOlow patients, two were treated with prednisolone 
(PSL) after being enrolled in this study; both improved. The remaining seven 
patients were followed throughout the observation period without treatment; 
one patient was treated with vitamins D and K. Thrombocytopenia remained 
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stable in three, spontaneously resolved in one, and progressed in four. One of 
the progressive patients eventually developed acute myeloid leukemia, 
which led to the patient’s death at 22 months after the diagnosis of HMT (Fig. 
S1B). 
As of July 2015, 19 of the 21 patients were alive. There was no 
difference in the four-year overall survival rates of the TPOhigh and TPOlow 
patient groups (88% vs. 89%) (Fig. 3A), while the three-year failure-free 
survival rate of the CsA-treated TPOhigh patients (100%) was significantly 
higher than that of the untreated TPOlow patients (20%, Fig. 3B).  
 
Discussion 
This prospective analysis revealed that 44% of HMT patients were positive 
for markers that were suggestive of immune pathophysiology; 28% had 
increased PNH-type cells and 44% had high TPO levels. These results were 
consistent with our previous observation that 15 of 29 patients (55%) with 
HMT showed increased percentages of PNH-type cells and a good response to 
CsA (unpublished observation). All the of the patients who were positive for 
PNH-type cells in the current study had high TPO levels and the TPOhigh 
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patients tended to show lower Hb levels than the TPOlow patients. Given the 
fact that two of the five TPOhigh patients who were followed without 
treatment developed AA, the lower Hb levels in the TPOhigh patients may be 
a feature of pre-AA.  
The immune-mediated destruction of haematopoietic stem or progenitor 
cells plays a central role in the pathophysiology of AA and inflammatory 
cytokines, such as IFN-γ, TNF-, and TGF- which are secreted from 
activated immune cells, are thought to inhibit haematopoiesis (El Mahgoub, 
et al 2014, Li, et al 2011, Nakao, et al 1997, Serio, et al 2011, Zeng and 
Katsanis 2015). Recent studies have shown that TGF- has suppressive 
effects on megakaryocyte/erythroid progenitor (MEP) proliferation (Akel, et 
al 2003, Xie, et al 2015, Zermati, et al 2000). Similar mechanisms to AA may 
exist in patients with HMT that manifests as thrombocytopenia alone, 
possibly because the levels of myelosuppressive cytokines that are present in 
the BM of patients with HMT are lower than those in patients with AA.  
Half of the TPOhigh patients in the current study who were treated with 
CsA showed improvement while two of the five TPOhigh patients who were 
followed without IST progressed to moderate AA. These findings also 
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indicate that TPOhigh HMT patients have a similar pathophysiology to 
patients with AA. Previous reports showed that some patients with chronic 
ITP that was refractory to PSL or -globulin responded well to CsA (Emilia, 
et al 2008, Emilia, et al 2002). These studies did not refer to the 
megakaryocyte cellularity in the BM of their patients. The megakaryocyte 
number is generally increased or normal in patients with ITP (Harker and 
Finch 1969, Houwerzijl, et al 2004, Louwes, et al 1999, Wintrobe and Greer 
2009). However, the recent diagnostic criteria proposed by the American 
Society Haematology and the British Society of Haematology do not 
necessitate a BM examination to assess megakaryocyte cellularity(2003, 
George, et al 1996). It is therefore possible that HMT patients who are 
responsive to CsA may be diagnosed as having ITP.  
Half of the TPOlow HMT patients who were followed without treatment 
showed the progression of cytopenia. It is known that both ITP and MDS 
patients show low TPO levels due to an increase in the number of 
megakaryocytes as well as the number of TPO receptors on megakaryocytes 
(Hou, et al 1998, Ogata and Tamura 2000, Tamura, et al 1998). In reality, 
two of our TPOlow HMT patients responded well to PSL – similarly to 
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patients with typical ITP - suggesting that the megakaryocyte cellularity in 
the BM may have been underestimated in the TPOlow HMT patients. 
Considering the fact that one of the 10 TPOlow HMT patients progressed to 
AML, TPOlow HMT patients should be followed carefully. Their BM should be 
examined if their platelet counts show further decreases in order to rule out 
MDS and AML.  
This interim analysis revealed that about half of the patients with HMT 
had a similar pathophysiology to AA, and suggested that early treatment 
with CsA may improve their prognosis. The evaluation of the number of 
PNH-type cells and the plasma TPO level might be useful for the appropriate 
management of patients with HMT. A long-term follow-up of a larger 
number of patients is necessary to clarify the impact of early CsA treatment 
on the prognosis of HMT. 
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Figure 1. The detection of PNH-type cells in HMT patients.  Scattergrams 
of three representative cases are shown. The numbers in the left upper 
quadrant represent PNH-type cell percentages. 
Figure 2. Changes in the platelet count with time in nine TPOhigh patients. 
Five of the six patients who received cyclosporine (CsA) therapy showed 
platelet recovery. None of the patients who were followed without therapy 
showed an increased platelet count. 
Figure 3. The overall survival rates (A) and failure-free survival rates in the 
TPOhigh patients (B). 
Figure S1. The treatment outcomes of the HMT patients. (A) The TPOhigh 
patient group. *Treatment with iron or anabolic steroids. (B) The TPOlow 
patient group. TPO, thrombopoietin; CsA, cyclosporine; w/o, without; Tx, 






Table I. Patient characteristics  
 Median (range) 
Age (year) 65 (25-79) 
male/female 14/11 
WBC (x109/L) 4.1 (2.77-8.50) 
Hb (g/dl) 11.9 (10.0-14.8) 
Platelet (x109/L) 40.0 (1.0-95.0) 
Positivity for PNH-type cells 7/25 
Clone size of granulocytes (%) 0.073 (0.015-20.5) 
Erythrocyte (%) 0.069 (0.0-3.8) 
Plasma TPO level (fmol/ml) 8.4 (0.4-42.8) 
WBC, white blood cell count; Hb, hemoglobin; PNH-type cells, paroxysmal 


























Table II. Relationships between plasma TPO levels and laboratory parameters. 
 TPOhigh (n=11) TPOlow (n=14) P value 
WBC (x109/L) 3.37 (3.3-8.5) 5.5 (2.8-7.8) 0.13 
Hb (g/dl) 11.2 (10.0-13.0) 12.4 (10.7-14.8) < 0.01 
Platelet (x109/L) 37.0 (6.0-75.0) 49.0 (1.0-95.0) 0.23 
MCV (fl) 104.6 (85.0-115.0) 96.8 (85.0-110.3) 0.19 
Positivity for PNH-type 
cells 
7 (64%) 0 (0%)  < 0.001 
WBC, white blood cell count; Hb, hemoglobin; PNH-type cells, paroxysmal nocturnal 





























Table III. Changes in the blood cell counts of TPOhigh patients responsive to CsA at 
12 months. 
 WBC (x109/L) Hb (g/dl) Platelet (x109/L) 
 before after before after before after 
Case 1 3.7 3.9 12.7 12.6 22.0 75.0 
Case 2 8.5 7.3 11.3 11.6 7.0 159.0 
Case 3 3.3 3.8 10.7 11.2 51.0 108.0 
Case 4 3.3 4.4 10.2 10.3 45.0 67.0 
Case 5 4.6 5.0 11.1 11.3 50.0 73.0 
WBC, white blood cell count; Hb, hemoglobin. 
 































Patients treated with CsA 
















Month after diagnosis 
10  
















































Treatment with CsA 
(n=6) 
Response to Tx, 5 





Progression of  
cytopenia, 2 
No treatment (n=3) 
Stable, 1 




Treatment with PSL 
(n=2) 
Response to Tx, 2 
Treatment  with 
Vit.D and K(n=1) 
Progression of  
cytopenia, 1 
No treatment (n=7) 




Progression of  
cytopenia, 2 
Progression to AML, 
1 
Supplementary 
Fig S1 
(A) (B) 
